TY  - JOUR 
AU  - Benavides, M.
AU  - Díaz-Rubio, E.
AU  - Carrato, A.
AU  - Abad, A.
AU  - Guillén, C.
AU  - Garcia-Alfonso, P.
AU  - Gil, S.
AU  - Cano, M. T.
AU  - Safont, M. J.
AU  - Gravalos, C.
AU  - Manzano, J. L.
AU  - Sánchez, A.
AU  - Alcaide, J.
AU  - López López, Rafael
AU  - Massutí, B.
AU  - Sastre, J.
AU  - Martínez, E.
AU  - Escudero, P.
AU  - Méndez, M.
AU  - Aranda, E.
PY  - 2019
SN  - 2059-7029
UR  - http://hdl.handle.net/20.500.11940/15378
AB  - Purpose: Metastatic colorectal cancer (mCRC) is a group of distinct diseases, with clinical and molecular differences between right-sided and left-sided tumours driving varying prognosis. Methods: Patients with KRAS/RAS-wild type (wt) mCRC treated in...
LA  - eng
KW  - Membrane Proteins
KW  - Adult
KW  - Middle Aged
KW  - GTP Phosphohydrolases
KW  - Time Factors
KW  - Proto-Oncogene Proteins p21(ras)
KW  - Disease Progression
KW  - Retrospective Studies
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Prognosis
KW  - Antineoplastic Agents
TI  - Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials
DO  - 10.1136/esmoopen-2019-000599
T2  - ESMO OPEN
M2  - e000599
KW  - CHUS
VL  - 4
ER  -